Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 19/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 11/20 | 0.65 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6093316 | 1.00 | PTGS2 (0.65) | PTGS2PTGS1P2RY6 | |
| SCHEMBL27916566 | 1.00 | PTGS2 (0.65) | PTGS2PTGS1P2RY6 | |
| SCHEMBL27648680 | 0.98 | PTGS2 (0.63) | PTGS2PTGS1P2RY6 | |
| Fluoride SCHEMBL28028189 | 0.98 | PTGS2 (0.63) | PTGS2PTGS1P2RY6 | |
| Trifluoroacetic Acid SCHEMBL27628779 | 0.95 | PTGS2 (0.60) | PTGS2PTGS1P2RY6 | |
| Benzene SCHEMBL6629703 | 0.93 | PTGS2 (0.62) | PTGS2PTGS1 | |
| SCHEMBL5667657 | 0.84 | P2RY6 (0.55) | PTGS2PTGS1P2RY6 | |
| SCHEMBL212846 | 0.83 | PTGS2 (0.59) | PTGS2PTGS1 | |
| SCHEMBL6094453 | 0.83 | PTGS2 (0.59) | PTGS2PTGS1 | |
| SCHEMBL6094984 | 0.83 | PTGS2 (0.67) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113330004-B | Differential solubility driven asymmetric conversion process for substituted 2H-chromene-3-carboxylic acids | 株式会社AskAt | 2023-11-17 | — | — | CN | claimed |
| EP-3906232-B1 | PROCESS FOR THE DIFFERENTIAL SOLUBILITY-DRIVEN ASYMMETRIC TRANSFORMATION OF SUBSTITUTED 2H-CHROMENE-3-CARBOXYLIC ACIDS | ASKAT INC (JP) | 2023-05-10 | — | — | EP | claimed |
| US-11555023-B2 | Process for the differential solubility-driven asymmetric transformation of substituted 2H-chromene-3-carboxylic acids | ASKAT INC. (JP) | 2023-01-17 | — | — | US | claimed |
| US-20220144792-A1 | PROCESS FOR THE DIFFERENTIAL SOLUBILITY-DRIVEN ASYMMETRIC TRANSFORMATION OF SUBSTITUTED 2H-CHROMENE-3-CARBOXYLIC ACIDS | ASKAT INC. (JP) | 2022-05-12 | — | — | US | claimed |
| EP-3906232-A1 | PROCESS FOR THE DIFFERENTIAL SOLUBILITY-DRIVEN ASYMMETRIC TRANSFORMATION OF SUBSTITUTED 2H-CHROMENE-3-CARBOXYLIC ACIDS | AskAt Inc. (JP) | 2021-11-10 | — | — | EP | claimed |
| CN-113330004-A | Differential solubility driven asymmetric transformation process for substituted 2H-chromene-3-carboxylic acids | 株式会社AskAt | 2021-08-31 | — | — | CN | claimed |
| WO-2020153279-A1 | PROCESS FOR THE DIFFERENTIAL SOLUBILITY-DRIVEN ASYMMETRIC TRANSFORMATION OF SUBSTITUTED 2H-CHROMENE-3-CARBOXYLIC ACIDS | ASKAT INC. (JP) | 2020-07-30 | — | — | WO | claimed |
| EP-3664800-A1 | THERAPEUTIC FORMULATIONS AND USES THEREOF | Piedmont Animal Health Inc. (US) | 2020-06-17 | — | — | EP | claimed |
| CN-110292575-A | Pharmaceutical composition | 株式会社ＡｓｋＡｔ | 2019-10-01 | — | — | CN | claimed |
| WO-2019032910-A1 | THERAPEUTIC FORMULATIONS AND USES THEREOF | PIEDMONT ANIMAL HEALTH LLC (US) | 2019-02-14 | — | — | WO | claimed |
| WO-2005016249-A2 | COMPOSITIONS OF A CHROMENE OR PHENYL ACETIC ACID CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND AN ACE INHIBITOR FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| WO-2004093895-A1 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A POTASSIUM ION CHANNEL MODULATOR FOR THE TREATMENT OF PAIN, INFLAMMATION OR INFLAMMATION MEDIATED DISORDERS | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | claimed |
| CN-1515566-A | Substituted chromene derivative for curing inflammation | G.D. | 2004-07-28 | — | — | CN | claimed |
| EP-0977748-B1 | SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2003-03-26 | — | — | EP | claimed |
| EP-1123285-A1 | SUBSTITUTED BENZOPYRAN ANALOGS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 2001-08-16 | — | — | EP | claimed |
| CN-1257489-A | Substituted benzopyran derivatives for the treatment of inflammation | SEARLE & CO (US) | 2000-06-21 | — | — | CN | claimed |
| WO-2000023433-A1 | SUBSTITUTED BENZOPYRAN ANALOGS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 2000-04-27 | — | — | WO | claimed |
| US-6034256-A | CYCLOOXYGEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-03-07 | — | — | US | claimed |
| EP-0977748-A1 | SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 2000-02-09 | — | — | EP | claimed |
| WO-1998047890-A1 | SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1998-10-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11555023-B2 | Process for the differential solubility-driven asymmetric transformation of substituted 2H-chromene-3-carboxylic acids | UACA, SLC7A1, CDYL | PTGS2 3076/4885PTGS1 4536/4885P2RY6 4650/4885 |
| US-20220144792-A1 | PROCESS FOR THE DIFFERENTIAL SOLUBILITY-DRIVEN ASYMMETRIC TRANSFORMATION OF SUBSTITUTED 2H-CHROMENE-3-CARBOXYLIC ACIDS | UACA, SLC7A1, CDYL | PTGS2 3076/4885PTGS1 4536/4885P2RY6 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.